

### The Madrid System for Business in Real Life

Orsolya Szentesi Head of Trademark Department

Egis Pharmaceuticals PLC



# **About the speaker**

Orsolya Szentesi



**Lawyer** – Hungarian national degree

MA in **IP law**Nice/Sophia Antipolis



Ministry of Education and Culture (EU affairs)

10+ years at **Egis Pharmaceuticals PLC** 





Pharma brand names

Use of **trademark symbols** 

# Tradition, expertise, quality



Foundation of the legal predecessor of Egis by Swiss Dr. Albert Wander and Hungarian Sándor Balla Budapest

1913

Commencement of API production **Budapest** 



1950



1976





1989

Start of injection production **Budapest** 

Egis became listed on the Budapest Stock Exchange

1994



# Tradition, expertise, quality





1995

French Servier acquired 51% Stake in Egis

Servier acquired 100% ownership of Egis

Egis launched
Europe's first
biosimilar monoclonal
antibody medicine

2013



2015

Modernisation of the active ingredient manufacturing infrastructure started Budapest

Egis strengthened its presence in the OTC market with the acquisition of Biovital in Poland The company inaugurated a brand new galenic plant Körmend



2021

2019



Two technology-intensive investments finished in Körmend:

- modernisation of the existing packaging infrastructure (1st phase)
- Inauguration of a plant for finished oncology products with special manufacturing requirements

# Vertically integrated leading regional pharmaceutical company





#### **Research and Development**

- State-of-the-art research laboratories
- Highly potent active ingredients, value-added generics, branded generics

# Contract manufacturing and development

active ingredients



# **Active Ingredient and Finished Product Production**

- Active ingredient synthesis
- Finished product formulation: tablets, capsules, injections, galenic forms
- Biosimilar: drug release testing secondary packaging
- Packaging



#### Sales

- 22% domestic
- 78% export

# Egis in numbers

**4560** colleagues

103 countries


es active ingredients

149

642 products

In the 2021/2022 business year our portfolio consisted of 642 products, belonging to 166 product lines containing 149 active ingredients.

### Main therapeutic areas



# More than 30 million patients are treated yearly with Egis medicines






181 million

boxes of drugs sold ...

Los Angeles - Budapest – Tokyo ...the length of the chain of boxes





**835 tons** active ingredients/

active ingredients, intermediates



5.6 billion

tablets and capsules 70% of the world population

#### Egis in the world



Egis products reach

103 countries

€ 577.6 million turnover in 2021/2022



18 countries, where Egis has its own marketing network

4560 colleagues





Sales **under the brand name Egis** through our subsidiaries and representative offices, respectively

#### Branded generic trademark filing strategy...



#### ...from Armenia to Viet Nam

#### Hungary

+

17 countries of operation

Armenia

Azerbaijan

**Bulgaria** 

Belarus

**Czech Republic** 

Georgia

Kazakhstan

Lithuania

Latvia

Moldova

**Poland** 

Romania

Russian


Federation

**Slovakia** 

Ukraine

Uzbekistan

Viet Nam





Sales **under the brand name Egis** through our subsidiaries and representative offices, respectively



Sales through our partners

# EGIS Trademark portfolio in numbers

of which 16592 are word trademarks (local script, block letters)
394 are figurative trademarks (306 without EGIS figurative marks)
57 are slogans
4 are colour marks

#### EGIS house mark is protected by

101 word trademarks

of which 7 trademarks with local script (China, India, Taiwan)


EGIS

**88 figurative trademarks** (means i.e.our company logo)



# Number of TM filings per year





### **Egis as TOP Madrid applicant**



#### A2. Top Madrid applicants, 2021

Ranking	Change in position from 2020	Madrid applicant	Origin	Madrid applications		
				2019	2020	2021
1	4	L'OREAL	France	193	116	171
2	2	ADP GAUSELMANN GMBH	Germany	39	123	120
3	8	GLAXO GROUP LIMITED	U.K.	59	64	110
4	-2	HUAWEI TECHNOLOGIES CO., LTD.	China	164	197	98
5	-4	NOVARTIS AG	Switzerland	129	233	94
6	1	EURO GAMES TECHNOLOGY LTD.	Bulgaria	48	84	93
7	1	APPLE INC.	U.S.	104	80	92
8	6	HENKEL AG & CO KGAA	Germany	77	60	90
9	-6	SHISEIDO COMPANY, LTD	Japan	70	133	89
10	-1	SYNGENTA CROP PROTECTION AG	Switzerland	30	78	85
11	0	SOCIETE DES PRODUITS NESTLE S.A.	Switzerland	41	64	76
12	13	EGIS GYA GYSZERGYA R ZRT.	Hungary	11	43	65
12	-2	RIGO TRADING S.A.	Luxembourg	102	70	65
14	13	RICHTER GEDEON NYRT.	Hungary	76	42	61
15	6	BEIERSDORF AG	Germany	47	47	60
16	20	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	Germany	38	34	58
16	-10	NINTENDO CO., LTD.	Japan	32	90	58
18	700	BATH & BODY WORKS BRAND MANAGEMENT, INC.	U.S.	27	6	57
19	-2	BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT	Germany	78	51	56
20	540	LG CORP.	Republic of Korea	3	7	55

#### Egis in numbers

4560 colleagues

103 countries

149 active ingredients

**642** products

In the 2021/2022 business year our portfolio consisted of 642 products, belonging to **166 product lines** containing 149 active ingredients.

#### Pharma Brand Names – Double Barriers







- accepted by trademark offices.
- not disputed by third parties.
   PREDICTABLE (more or less)



#### **REGULATORY BARRIER**

#### A name must be:

• accepted by health agencies.


UNPREDICTABLE (strict decisions)

#### Pharma Brand Names - Double Barriers









**REGULATORY BARRIER** 

Reasons for rejection

- Lack of distinctiveness
- Similar to earlier TM

Artificial example for an **ibuprofen** product

- Similar to earlier brand name (also under evaluation; counting identical letters)
- Similar to INN\* IBUFENOR (sim. to own INN), PAREMO (sim. to diff. INN paracetamol)
- Contains INN stem ZYTPROFEN (-profen)
- Promotional/meaningful DOLYXHELP
- Containing (part of) company name EGIBUP

#### Pharma Brand Names – Double Barriers








#### **SOLUTION:**

- unusual brand names
- multiplication of TMs dedicated to 1 product

# Number of TM filings per year





#### Why Madrid?



Hungary + 17 countries Armenia, Azerbaijan, Bulgaria, Belarus, Czech Rep., Georgia, Kazakhstan, Lithuania, Latvia, Moldova, Poland, Romania, Russia, Slovakia, Ukraine, Uzbekistan, Viet Nam



Predictable timing

National TM filing proceedings
3-36 months

VS.

WIPO 12/18 months

vs. EUTM: legallysafer



Lower number of earlier rights

**27 national TM registries** including in WEU

VS.

8 national TM registries in CEU

#### Why Madrid?



Hungary + 17 countries Armenia, Azerbaijan, Bulgaria, Belarus, Czech Rep., Georgia, Kazakhstan, Lithuania, Latvia, Moldova, Poland, Romania, Russia, Slovakia, Ukraine, Uzbekistan, Vietnam



Cheaper

# Cost of national TM applications in 1 class in 17 countries

Official fee cca. EUR 5714\*

+

Local agent fee min EUR 6800 (EUR 400/country)

Madrid fee in 1 class (basic fee + countries) + forwarding fee from basic office to WIPO

Sum:

Cca. **EUR 12.500** 



Cca. EUR 3.709

Less administration



- instructions / contract
- docketing
- payment arrangement

17 x Local agents cca. 17x 1 hour vs.


1x Madrid e-filing cca. 1 hour

Paralegal /
Admin.
assistant

<sup>\*</sup>Source: https://www.country-index.com/country\_surveys.aspx

# Number of TM filings per year








#### WHO FILED THE MOST MADRID TRADEMARK APPLICATIONS IN 2013?

FILINGS UNDER THE MADRID SYSTEM FOR THE INTERNATIONAL REGISTRATION OF MARK









2013111 applications

2014132 applications






2024?

# Thank you for your attention





Source: WIPO Global Barnd Database - Vienna cl. 5.13.15 Christmas trees, branches of Christmas trees Global Brand Database (wipo.int)